While genetically engineered BiTEs from dual scFv fragments to CD3 and either EpCAM or CD19 have shown significant anti-tumor activity in the clinic [28–30], it is advantageous to utilize readily available intact tumor specific antibodies. Here, CD19 is linked to neoplasm.